...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Cancer Research and Therapeutics >CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5
【24h】

CD20 negative primary diffuse large B cell lymphoma of breast: Role of Pax-5

机译：乳腺癌CD20阴性的原发性弥漫性大B细胞淋巴瘤：Pax-5的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pax-5 is a B cell marker, the expression of which is detectable in as early as the pro B stage, and subsequently, in all further stages of B cell development except the plasma cells. Malignant lymphomas of breast are uncommon and occur as either primary or secondary lesions. Primary lymphoma is a rare disorder of breast and constitutes less than 0.6% of all breast malignancies and 2.2% of extranodal lymphomas. We report an unusual case of CD20 negative Pax-5 positive primary diffuse large B cell lymphoma (DLBCL) of breast. The case highlights the diagnostic challenge posed by extranodal CD20 negative DLBCL. Pax-5 immunohistochemistry has diagnostic benefit as a B-cell marker in the work-up of undifferentiated malignant neoplasms. Although it is available for nearly a decade now, it is not widely used. Pax-5 is a valuable addition to the armamentarium of markers currently available for lymphoma subtyping.
机译：Pax-5是一种B细胞标记物，其表达可在pro B阶段以及随后的B细胞发育的所有其他阶段（浆细胞除外）中检测到。乳腺恶性淋巴瘤不常见，可作为原发性或继发性病变发生。原发性淋巴瘤是一种罕见的乳腺疾病，仅占所有乳腺恶性肿瘤的0.6％和结外淋巴瘤的2.2％。我们报告了CD20阴性Pax-5阳性乳腺原发性弥漫性大B细胞淋巴瘤（DLBCL）的罕见病例。该病例突出了结外CD20阴性DLBCL带来的诊断挑战。 Pax-5免疫组织化学作为B细胞标记物在未分化恶性肿瘤的检查中具有诊断优势。尽管现在已经有将近十年的历史了，但并未得到广泛使用。 Pax-5是目前可用于淋巴瘤亚型分型的标记物的重要补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号